EGF‐R and Overexpression of the Oncogene c‐erbB‐2 in Ovarian Cancer: Immunohistochemical Findings and Prognostic Value

H. Meden, D. Marx, T. Raab, M. Kron, A. Schauer, W. Kuhn

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

Purpose: The purpose of this study was to investigate the prognostic value of EGF‐R (c‐erbB‐1) compared to the overexpression of the c‐erbB‐2 oncogene product p185 in ovarian cancer. Patients and methods: The study was conducted on 266 previously untreated ovarian cancer patients with FIGO stage I–IV disease. EGF‐R and c‐erbB‐2 oncogene product p185 have been evaluated using immunohistochemistry. Survival times were analyzed according to the method described by Kaplan and Meier. For the simultaneous evaluation of the prognostic relevance of the analyzed factors, a Cox proportional hazards regression was performed. Results: EGF‐R was detected in 13%, and c‐erbB‐2 oncogene product p185 in 18% of primary tumors. EGF‐R showed no significant impact on the survival time, whereas c‐erbB‐2 oncogene product p185 positive patients had a significantly worse prognosis compared to p185 negative cases (p = 0.002). In the multivariate analysis, c‐erbB‐2 oncogene product p185, like tumor stage, histological grade and age, was found to be a significant prognostic factor. Conclusion: These data confirm the prognostic importance of the c‐erbB‐2; oncogene product p185 in ovarian cancer at the time of primary surgery, while EGF‐ R does not seem to have prognostic relevance.

Original languageEnglish
Pages (from-to)167-178
Number of pages12
JournalJournal of Obstetrics and Gynaecology
Volume21
Issue number2
DOIs
StatePublished - Apr 1995
Externally publishedYes

Keywords

  • EGF‐R
  • c‐erbB‐2
  • membrane protein
  • oncogene
  • ovarian cancer

Fingerprint

Dive into the research topics of 'EGF‐R and Overexpression of the Oncogene c‐erbB‐2 in Ovarian Cancer: Immunohistochemical Findings and Prognostic Value'. Together they form a unique fingerprint.

Cite this